According to Zacks, “PolyPid Ltd. is a pharmaceutical company. It discovers, develops and commercializes antibiotic drugs for the prevention of surgical infections. The company’s product candidate includes D-PLEX100, BONYPID-1000 and BONYPID-500 which are in clinical stage. PolyPid Ltd. is based in Petach Tikva, Israel. “
Separately, Raymond James upgraded PolyPid from an “outperform” rating to a “strong-buy” rating in a research note on Tuesday, November 24th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $25.50.
Shares of PYPD opened at $14.32 on Tuesday. PolyPid has a 12-month low of $8.64 and a 12-month high of $19.45. The stock’s 50-day moving average price is $10.83 and its 200 day moving average price is $11.38.
PolyPid (NASDAQ:PYPD) last released its quarterly earnings data on Wednesday, February 10th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.32. Analysts anticipate that PolyPid will post -1.8 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Services Advisors Inc. bought a new stake in PolyPid during the 4th quarter worth approximately $700,000. Federated Hermes Inc. bought a new stake in PolyPid during the 3rd quarter worth approximately $495,000. BlackRock Inc. bought a new stake in PolyPid during the 3rd quarter worth approximately $48,000. Finally, ARK Investment Management LLC bought a new stake in PolyPid during the 3rd quarter worth approximately $445,000. Institutional investors and hedge funds own 3.60% of the company’s stock.
PolyPid Company Profile
PolyPid Ltd. develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in pivotal Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.